New Alzheimer’s Drugs Raise Questions for Regulators

Key Points Summary

• • New Alzheimer’s drugs such as donanemab and lecanemab are generating optimism but remain controversial due to modest clinical benefits, safety concerns, and high costs.
  • Regulatory agencies in the US, UK, and Europe have reached different conclusions regarding approvals and patient access.
  • Amyloid-related imaging abnormalities (ARIA) remain a significant safety concern requiring monitoring through MRI scans and genetic testing.
  • Researchers are expanding beyond amyloid-targeted therapies and investigating inflammation, infections, and metabolic pathways.
  • More than 150 investigational drugs are currently being evaluated to improve outcomes and quality of life for patients with Alzheimer’s disease.
  • For More Updates in Neurology, register for the American Neurology Summit 2026

Alzheimer’s Drugs Face Global Regulatory Divide Amid Safety Debate

Alzheimer’s disease (AD) remains one of the greatest challenges in neurology, affecting millions worldwide and placing growing pressure on healthcare systems. While a new generation of Alzheimer’s drugs has offered hope for slowing disease progression, regulators across different regions continue to debate whether the benefits justify the risks and costs.

Recent discussions highlighted in The Lancet reveal how differing interpretations of clinical data have led to conflicting approval decisions, creating uncertainty for clinicians, patients, and healthcare policymakers.

Why Are Regulators Divided Over New Alzheimer’s Drugs?

Several recently approved disease-modifying therapies focus on removing amyloid-beta plaques, a hallmark feature of Alzheimer’s disease. Among the most closely watched treatments are donanemab and lecanemab, both of which demonstrated an ability to slow cognitive decline in patients with early symptomatic AD.

Clinical studies reported that donanemab reduced disease progression by approximately 35% over 72 weeks, while lecanemab slowed decline by 27% over 18 months using separate assessment scales. However, neither treatment reverses symptoms or cures the disease.

A major concern is the occurrence of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling and microbleeds. In pivotal studies, ARIA occurred more frequently among treated patients than among those receiving a placebo. Although clinicians can monitor risks through genetic screening and periodic MRI evaluations, regulators continue to weigh whether these safety concerns offset the observed benefits.

The regulatory response has varied significantly. The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved both donanemab and lecanemab, while European regulators initially rejected the therapies before later recommending restricted use in carefully selected patient populations.

Patient Access Remains a Major Challenge

Approval does not automatically guarantee access. Healthcare systems must also evaluate cost-effectiveness, especially when clinical gains are modest.

In the United Kingdom, the National Institute for Health and Care Excellence (NICE) concluded that the benefits of donanemab and lecanemab did not initially justify their costs for routine National Health Service coverage. The decision sparked renewed discussions regarding caregiver burden, patient quality of life, and the broader societal impact of Alzheimer’s disease.

Explore All Neurology CME Conferences & Online Courses, and also Checkout American Neurology Summit 2026

For healthcare professionals, these developments underscore the importance of balancing efficacy, safety monitoring, patient expectations, and healthcare resource allocation when considering treatment options.

What Is the Future of Alzheimer’s Disease Treatment?

Researchers increasingly believe that successful intervention may require treatment before symptoms become apparent. Ongoing clinical trials are evaluating therapies in high-risk individuals and investigating biological pathways beyond amyloid accumulation.

Emerging candidates such as trontinemab aim to reduce amyloid burden while minimizing safety concerns. At the same time, scientists are studying inflammation, infections, and metabolic dysfunction as potential contributors to disease progression.

With more than 150 investigational therapies currently under development, the field is gradually shifting toward precision medicine and multi-target treatment strategies. Future success will likely depend on therapies that not only modify biological markers but also preserve memory, maintain independence, and improve daily functioning.

For HCPs and nurses, the evolving landscape highlights a critical question: should treatment decisions focus primarily on slowing disease progression, or should meaningful improvements in patient quality of life remain the ultimate benchmark?

Source:

The Lancet